This study aims to explore the clinical advantages of biosimilar drugs in blood glucose control of diabetes, and analyze the challenges and coping strategies. This paper discusses the advantages of biosimilars through a review. The analysis reveals that biosimilar drugs have significant cost-effectiveness, improved patient affordability, and ease of clinical use in diabetic glycemic control. At the same time, through education, monitoring and scientific conversion strategies, the challenges of doctors and patients, immunogenicity and safety monitoring can be overcome. Biosimilar drugs have important clinical value in the field of diabetes treatment, which provide new perspectives and methods for improving the treatment effect, improving the quality of life of patients, and optimizing the allocation of medical resources. Medical professionals, patients, and policy makers should work together to promote the rational application of biosimilar medicines.
Read full abstract